• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Stryker Corporation

    5/30/25 4:16:27 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    S-8 1 d36650ds8.htm S-8 S-8

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    STRYKER CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Michigan   38-1239739

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    1941 Stryker Way, Portage, Michigan   49002
    (Address of Principal Executive Offices)   (Zip Code)

    2008 EMPLOYEE STOCK PURCHASE PLAN

    2011 LONG-TERM INCENTIVE PLAN

    (Full title of the plan)

    Tina S. French

    Vice President, Corporate Secretary

    Stryker Corporation

    1941 Stryker Way, Portage, Michigan 49002

    (Name and address of agent for service)

    (269) 385-2600

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Small reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by Stryker Corporation (“Stryker”, the “Company”, “we”, “us” or “our”) to register (i) an additional 1,500,000 shares of Common Stock, par value $.10 per share (the “Common Stock”), of Stryker issuable under Stryker’s 2008 Employee Stock Purchase Plan (as amended and restated, the “ESPP”), and (ii) an additional 15,000,000 shares of Common Stock issuable under Stryker’s 2011 Long-Term Incentive Plan (as amended and restated, the “LTIP” and, together with the ESPP, the “Plans”), which shares of Common Stock are securities of the same class and relate to the same Plans as those shares registered on the Company’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “SEC”) (a) with respect to the ESPP, on April 23, 2008 (File No. 333-150396) and December 8, 2017 (File No. 333-221959) and (b) with respect to the LTIP, on January 24, 2012 (File No. 333-179142) and December 8, 2017 (File No. 333-221958) (collectively, the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, this Registration Statement on Form S-8 incorporates by reference the contents of the Prior Registration Statements, except to the extent supplemented, amended or superseded by the information set forth herein, and the shares of Common Stock registered hereunder with respect to the Plans are in addition to the shares of Common Stock registered on such Prior Registration Statements with respect to each such Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed with the SEC by Stryker are hereby incorporated into this Registration Statement by reference (other than information in such filings deemed, under SEC rules or otherwise, not to have been filed with the SEC):

     

      1.

    Stryker’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 12, 2025;

     

      2.

    All other reports filed by Stryker pursuant to Section 13(a) or 15(d) of the Securities Exchange Act since December 31, 2024; and

     

      3.

    The description of Stryker’s Common Stock contained in the Registration Statement on Form 8-A filed with the SEC under the Exchange Act on July  1, 1997, as updated by the description of Stryker’s Common Stock included in Exhibit 4(xxv) to Stryker’s Annual Report on Form 10-K for the year ended December 31, 2024, together with any amendment or report filed for the purpose of updating such description.

    In addition, all documents filed by Stryker pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this Registration Statement (other than information in such filings deemed, under SEC rules or otherwise, not to have been filed with the SEC), and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document that is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 5. Interests of Named Experts and Counsel

    The validity of the Common Stock to be issued under this Registration Statement has been passed upon by Robert F. Pomper, Senior Corporate Operations Counsel. Mr. Pomper is eligible to purchase Common Stock granted pursuant to the ESPP and beneficially owns shares of Common Stock and options to purchase Common Stock granted pursuant to the LTIP.

    Item 6. Indemnification

    Our Bylaws, as amended (our “bylaws”), require us to indemnify our directors and certain officers as designated by our Board of Directors from time to time to the fullest extent authorized or permitted by law (as now or hereafter in effect). Such right to indemnification continues as to a person who has ceased to be a director or designated officer and inures to the benefit of his or her heirs, executors and personal and legal representatives. However, except for proceedings to enforce rights to indemnification, we are not obligated to indemnify any director or designated officer (or his or her heirs, executors or personal or legal representatives) in connection with a proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was authorized or consented to by our Board of Directors. The right to indemnification includes the right to be paid by Stryker, promptly as incurred, the reasonable expenses of defending or otherwise participating in any action, suit or proceeding in advance of its final disposition upon receipt of a written undertaking executed by or on behalf of such director or designated officer to repay the advance if it is ultimately determined that he or she did not meet the standard of conduct, if any, required for the indemnification of a person under the circumstances. We may, to the extent authorized from time to time by our Board of Directors, provide rights to indemnification and to the advancement of expenses to other officers, employees and agents of Stryker. These rights to indemnification and to the advancement of expenses are not exclusive of any other right that any person may have or hereafter acquire under our bylaws, our Restated Articles of Incorporation, as amended (our “articles”), any statute, agreement, vote of shareholders or disinterested directors or otherwise. Any repeal or modification of the relevant sections of our bylaws will not adversely affect any rights to indemnification and to the advancement of expenses of a director or designated officer existing at the time of such repeal or modification with respect to any acts or omissions occurring prior to such repeal or modification.

    Under our bylaws, we also have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of Stryker or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity or arising out of his or her status as such, whether or not we would have the power to indemnify him or her against such liability under applicable law. We maintain directors’ and officers’ liability insurance, with customary terms and subject to customary exclusions, under which our directors and officers are insured against certain losses as a result of certain claims brought against them in such capacities.

    Our articles provide that, to the full extent authorized or permitted by the Michigan Business Corporation Act (the “MBCA”), directors of Stryker will not be personally liable to Stryker or its shareholders for any acts or omissions in such person’s capacity as a director. Any amendment, alteration or repeal of such provision of our articles by our shareholders will not adversely affect any right or protection of a director of Stryker for or with respect to any act or omission of such director occurring prior to, or at the time of, such amendment, alteration or repeal.

    Section 561 of the MBCA provides that a Michigan corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative and whether formal or informal), other than an action by or in the right of the corporation, by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, partner, trustee, employee or agent of another


    foreign or domestic corporation, partnership, joint venture, trust or other enterprise, whether for profit or not, against expenses, including attorneys’ fees, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action, suit or proceeding if the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation or its shareholders, and with respect to any criminal action or proceeding, if the person had no reasonable cause to believe his or her conduct was unlawful. In addition, Section 562 of the MBCA provides that a Michigan corporation may indemnify a person who was or is a party or is threatened to be made a party to a threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, partner, trustee, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise, whether for profit or not, against expenses, including attorneys’ fees and amounts paid in settlement actually and reasonably incurred by the person in connection with the action or suit, if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation or its shareholders. The MBCA does not permit indemnification for a claim, issue or matter in which the person has been found liable to the corporation unless application for indemnification is made to, and ordered by, the court conducting the proceeding or another court of competent jurisdiction.

    Section 563 of the MBCA provides that a director or officer who has been successful on the merits or otherwise in defense of an action, suit or proceeding referred to in Sections 561 and 562 of the MBCA, or in defense of a claim, issue, or matter in the action, suit, or proceeding, shall be indemnified by the corporation against actual and reasonable expenses, including attorneys’ fees, incurred by him or her in connection with the action, suit or proceeding, and an action, suit, or proceeding brought to enforce this mandatory indemnification.

    We have entered into indemnification agreements with each of our directors and officers.

    The foregoing statements are subject to the detailed provisions of the MBCA, our articles and our bylaws.

    Item 8. Exhibits

    The exhibits to this Registration Statement are listed below:

     

      4.

    Instruments defining the rights of security holders, including indentures.

     

      (i)

    Restated Articles of Incorporation—Incorporated by reference to Exhibit 3(i) to the Company’s Form 10-Q for the quarterly period ended September 30, 2018 (File No. 00-09165)

     

      (ii)

    Amended and Restated Bylaws—Incorporated by reference to Exhibit 3(ii) to the Company’s Form 10-K for the year ended December 31, 2022 (File No. 001-13149)

     

      5.

    Opinion re legality.

     

      (i)

    Opinion of Robert F. Pomper, Senior Corporate Operations Counsel.*

     

      23.

    Consent of experts and counsel.

     

      (i)

    Consent of Ernst  & Young LLP, Independent Registered Public Accounting Firm of the Company.*

     

      (ii)

    The consent of Robert F. Pomper, Senior Corporate Operations Counsel, is contained in the opinion filed as Exhibit 5(i) to this Registration Statement.*

     

      24.

    Power of attorney.

     

      (i)

    Included as part of the signature pages hereto.*

     

      99.

    Additional exhibits.


      (i)

    2008 Employee Stock Purchase Plan, as Amended and Restated—Incorporated by reference to Appendix D to the Proxy Statement for the Company’s 2025 Annual Meeting of Shareholders (File No. 001-13149).

     

      (ii)

    2011 Long-Term Incentive Plan, as Amended and Restated—Incorporated by reference to Appendix B to the Proxy Statement for the Company’s 2025 Annual Meeting of Shareholders (File No. 001-13149).

     

      107.

    Filing Fee Table.*

     
    *

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant, Stryker Corporation, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portage, State of Michigan, on May 30, 2025.

     

    STRYKER CORPORATION
    By:  

    /s/ Preston W. Wells

      Preston W. Wells
      Vice President, Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Tina S. French and Austin Y. Ke, and each of them, with full power of substitution and resubstitution, as attorneys or attorney to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file with the SEC the same, with all exhibits thereto, and any and all applications or other documents to be filed with the SEC pertaining thereto, with full power and authority to do and perform any and all acts and things whatsoever required and necessary to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, hereby ratifying and confirming all that said attorneys, and any of them and any such substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on May 30, 2025.

     

    Signature

      

    Title

    /s/ Kevin A. Lobo

       Chair, Chief Executive Officer and President
    Kevin A. Lobo    (Principal Executive Officer)

    /s/ Preston W. Wells

       Vice President, Chief Financial Officer
    Preston W. Wells    (Principal Financial Officer)

    /s/ William E. Berry, Jr.

       Vice President, Chief Accounting Officer
    William E. Berry, Jr.    (Principal Accounting Officer)

    /s/ Sherilyn S. McCoy

       Lead Independent Director
    Sherilyn S. McCoy   

    /s/ Mary K. Brainerd

       Director
    Mary K. Brainerd   

    /s/ Giovanni Caforio, M.D.

       Director
    Giovanni Caforio, M.D.   


    /s/ Emmanuel P. Maceda

       Director
    Emmanuel P. Maceda   

    /s/ Rachel M. Ruggeri

       Director
    Rachel M. Ruggeri   

    /s/ Andrew K. Silvernail

       Director
    Andrew K. Silvernail   

    /s/ Lisa M. Skeete Tatum

       Director
    Lisa M. Skeete Tatum   

    /s/ Ronda E. Stryker

       Director
    Ronda E. Stryker   

    /s/ Rajeev Suri

       Director
    Rajeev Suri   
    Get the next $SYK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

      Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre

      5/19/25 1:01:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker reports first quarter 2025 operating results

      Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        13.4        %         (0.8)        %         14.2        %         3.5        %         10.7        %Orthopaedics    

      5/1/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Financials

    Live finance-specific insights

    See more
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker reports first quarter 2025 operating results

      Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        13.4        %         (0.8)        %         14.2        %         3.5        %         10.7        %Orthopaedics    

      5/1/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

      Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

      2/19/25 8:30:00 AM ET
      $NARI
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/12/24 10:18:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/14/23 12:37:55 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/10/23 9:18:16 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    See more

    $SYK
    SEC Filings

    See more

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

      Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

      3/11/25 8:03:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Kadant Set to Join S&P SmallCap 600

      NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

      2/13/25 5:54:00 PM ET
      $KAI
      $NARI
      $SPGI
      $SYK
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

      Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

      1/28/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Stryker Corporation

      S-8 - STRYKER CORP (0000310764) (Filer)

      5/30/25 4:16:27 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Stryker Corporation

      SD - STRYKER CORP (0000310764) (Filer)

      5/23/25 10:35:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STRYKER CORP (0000310764) (Filer)

      5/13/25 5:29:41 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr covered exercise/tax liability with 1,005 shares, decreasing direct ownership by 28% to 2,643 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:43:32 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr sold $211,370 worth of shares (755 units at $279.96), decreasing direct ownership by 29% to 1,853 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:39:38 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Director Maceda Emmanuel Perez was granted 560 shares (SEC Form 4)

      4 - STRYKER CORP (0000310764) (Issuer)

      5/14/25 4:25:34 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Citigroup resumed coverage on Stryker with a new price target

      Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

      2/26/25 7:17:53 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

      12/2/24 7:02:55 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Stryker with a new price target

      Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

      9/10/24 8:01:33 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care